Washington Post Publisher Will Lewis Steps Down After Layoffs 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
ST. LOUIS PARK, Minn., Jan. 22, 2018 -- NeoChord, Inc., a privately-held medical technology company leading the advancement of minimally invasive valve repair for degenerative mitral regurgitation (DMR), today announced a research collaboration with the Skirball Center for Innovation (SCI) at the Cardiovascular Research Foundation (CRF) to accelerate development of the company’s transcatheter program.
“We are delighted to partner with an organization aiming to transform the treatment of mitral valve repair using catheter-based techniques,” said Juan F. Granada, MD, President and Chief Executive Officer of CRF. “Transcatheter mitral valve repair provides a less invasive delivery option and expands the therapeutic options that patients have today. We look forward to collaborating with NeoChord on their transcatheter program to work toward improved quality of life for patients afflicted with mitral regurgitation.”
The Cardiovascular Research Foundation is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. For over 20 years, SCI has contributed to key advances in the treatment of cardiovascular disease and has played an essential role in bringing innovative new technologies, pharmacologic therapies, and treatment paradigms to patients.
“CRF has been instrumental in the rapid progress of innovation in interventional cardiology by establishing the safe use of new technologies and therapies for heart disease,” said David Chung, President and Chief Executive Officer of NeoChord. “This research collaboration provides NeoChord with access to world-renowned clinicians, researchers, and animal lab facilities as we move our transcatheter program through preclinical development.”
About NeoChord, Inc.
Founded in 2007 and based in St. Louis Park, Minnesota, NeoChord, Inc. is a privately held medical technology company leading the advancement of minimally invasive repair for DMR. NeoChord’s DS1000 system received CE market clearance in December 2012. NeoChord received IDE approval from the FDA for the US pivotal trial in May 2016. For more information, please visit the Company's website at www.neochord.com.
The NeoChord DS1000 System is CE marked and approved for sale in Europe.
CAUTION: Investigational Device Limited by Federal (United States) Law to Investigational Use.
NEOCHORD, DS1000, RECHORD, the stylized logos, and Transforming Mitral Valve Repair are registered trademarks or service marks of the NeoChord Corporation.
Contact:
Bruce Van Deman
NeoChord, Inc.
(952) 698-7812 or (949) 413-1301
[email protected]
